YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Dermatomyositis.

Bivamelagon is under clinical development by Rhythm Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate ...

which will allow officials to meet with counterparts at departments and agencies ahead of the January transition of power. Pushpa 2 box office Day 13: Allu Arjun's film remains unstoppable People ...